ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2020 and some content may be unavailable. To unlock all content for 2020, please visit the archives.

Abstract: PO0027

Use of Ibuprofen and the Risk of Hospital-Acquired AKI in Children

Session Information

Category: Acute Kidney Injury

  • 101 AKI: Epidemiology, Risk Factors, and Prevention

Authors

  • Su, Licong, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
  • Li, Yanqin, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
  • Xu, Xin, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Background

Ibuprofen is widely used in children worldwide, especially in children with cancer, fever or trauma. However, large and high-quality studies on the association between ibuprofen and acute kidney injury (AKI) in children have been lacking.

Methods

The Epidemiology of AKI in Chinese Hospitalized patients (EACH2 study) is a multicenter, retrospective study of 3,044,023 patients admitted from 2013 to 2015 at 25 academic medical centers in China. Patient-level data were obtained from the electronic hospitalization information system. We included 50,420 hospitalized children aged between 1 month to 18 years who had at least one SCr test during the first 3 days and any interval between two continuous SCr testing <14 days during the first 30 days of hospitalization, excluding those with end-stage renal disease, community-acquired AKI, insufficient SCr testing and without prescription. AKI was defined as an increase in SCr by 26.5 μmol/L within 48 hours or a 50% increase in SCr from the baseline. We estimated the effect of exposure to ibuprofen on the risk of HA-AKI using a COX proportional hazard model with adjustment for age, sex, standardized baseline creatinine, comorbidities, clinical procedures, other nephrotoxic drugs use and stratification by hospital and division. We also compared the effect sizes of ibuprofen among subgroups stratified by age, gender, chronic kidney disease, need for intensive care and exposure to other nephrotoxic drugs.

Results

Among 50,420 children who met the inclusion and exclusion criteria, 5,526 (11.0%) were ibuprofen users, and 3,476 (6.9%) had HA-AKI during hospitalization. Ibuprofen use was associated with significantly increased risk of HA-AKI (hazard ratios,1.23; 95% CI, 1.14-1.34) after adjusting for confounders. The greater nephrotoxicity of ibuprofen was observed in children who had chronic kidney disease, required intensive care, or were of elder age.

Conclusion

Ibuprofen was widely used and associated with an increased risk of HA-AKI in hospitalized children in China.

Use of ibuprofen and the risk of HA-AKI in patients by Cox proportional hazard
 Total, NNo. of AKICrude HR
(95% CI)
P valueAdjusteda HR
(95% CI)
P value
Non-user44,8943,049Reference Reference 
Ibuprofen5,5264271.36 (1.27-1.46)<0.0011.23 (1.14-1.34)<0.001

a: Adjusted age, sex, standardized baseline creatinine, comorbidities, clinical procedures, other nephrotoxic drugs use and stratified by hospital and division.